November 12th, 2026Digital Gradebook Engagement Scores May Flag Adolescents at Risk for Substance UseTeacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.Read more
November 20th, 2026Podcast: Bessel van der Kolk, MD, on Trauma, Attachment, and the Limits of Pharmacotherapy for PTSDBessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.Read more
November 20th, 2026Emestedastat for Alzheimer Disease Falls Short Overall, Signals Subgroup BenefitEmestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.Read more
November 20th, 2026Long-Acting Injectable Antipsychotics: Balancing Evidence, Ethics, and Patient CareIn this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.Read more
November 19th, 2026Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 YearsLeqembi shows lower progression rate in Alzheimer disease over 3 years, shows new data.Read more
November 17th, 2026Mixed Results From Phase 3 Data for AR1001 in Alzheimer DiseaseNew phase 3 data for a PDE-5 inhibitor in Alzheimer disease.Read more
November 16th, 2026Morning Rounds: News From November 9-16Review news from the last week in pharmacology, legislation, and research. Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more